IBIO 202
Alternative Names: IBIO-202Latest Information Update: 24 Feb 2022
At a glance
- Originator iBio Inc
- Class COVID-19 vaccines; Subunit vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 14 Feb 2022 iBio plans to file an IND application with the US FDA for COVID-2019 infections before December 2022
- 08 Dec 2021 iBio collaborates with a leading innovator of microarray patch systems for intramuscular injections of IBIO 202
- 29 Nov 2021 Preclinical trials in COVID-2019 infections (Prevention) in USA (IM)